These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
37-1744899
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
1450 Centrepark Boulevard, Suite 210
West Palm Beach, Florida
|
33401
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Large accelerated filer
ý
|
Accelerated filer
o
|
Non-Accelerated filer
o
|
Smaller reporting company
o
|
|
|
|
|
Emerging growth company
o
|
|
Class
|
April 27, 2018
|
|
Common Stock, par value $0.01 per share
|
288,125,974 shares
|
|
|
Page
|
|
|
|
|
|
|
|
||
|
|
||
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
Condensed Consolidated Statements of Operations
|
|
|
|
Three Months Ended March 31, 2018 and 2017
|
|
|
|
Condensed Consolidated Statements of Comprehensive Income (Loss)
|
|
|
|
Three Months Ended March 31, 2018 and 2017
|
|
|
|
Condensed Consolidated Balance Sheets
|
|
|
|
March 31, 2018 and December 31, 2017
|
|
|
|
Condensed Consolidated Statements of Cash Flows
|
|
|
|
Three Months Ended March 31, 2018 and 2017
|
|
|
|
Condensed Consolidated Statements of Changes in Stockholders' Equity
|
|
|
|
Three Months Ended March 31, 2018 and 2017
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
Terms
|
|
Definitions
|
|
Platform; We; Us; Our; the Company; PSP
|
|
Platform Specialty Products Corporation, a Delaware corporation, and its subsidiaries, collectively.
|
|
AIs
|
|
Active ingredients.
|
|
Amended and Restated Credit Agreement
|
|
Platform’s Second Amended and Restated Credit Agreement, dated as of August 6, 2014, among, inter alia, Platform, MacDermid Holdings, LLC, MacDermid, the subsidiaries of Platform and MacDermid Holdings, LLC from time to time parties thereto, the lenders from time to time parties thereto and Barclays Bank PLC, as administrative agent and collateral agent, as amended and restated from time to time.
|
|
Arysta
|
|
Arysta LifeScience Limited, a formerly Irish private limited company.
|
|
Arysta Acquisition
|
|
Acquisition of a 100% interest in Arysta, completed on February 13, 2015.
|
|
Arysta Seller
|
|
Nalozo, L.P., an affiliate of Nalozo S.à.r.l., a Luxembourg limited liability company and the original seller in the Arysta Acquisition.
|
|
ASU
|
|
Accounting Standards Update.
|
|
Board
|
|
Platform’s board of directors.
|
|
Credit Facilities
|
|
The First Lien Credit Facility and the Revolving Credit Facility, collectively, available under the Amended and Restated Credit Agreement.
|
|
DuPont
|
|
E.I. du Pont de Nemours and Company, now known as DowDuPont Inc.
|
|
EBITDA
|
|
Earnings before interest, taxes, depreciation and amortization.
|
|
ESPP
|
|
Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan.
|
|
Exchange Act
|
|
Securities Exchange Act of 1934, as amended.
|
|
FASB
|
|
Financial Accounting Standard Board.
|
|
First Lien Credit Facility
|
|
First lien credit facility available under the Amended and Restated Credit Agreement.
|
|
Founder Entities
|
|
Mariposa Acquisition, LLC and Berggruen Holdings Ltd. and its affiliates, collectively.
|
|
GAAP
|
|
Generally accepted accounting principles in the United States.
|
|
MacDermid
|
|
MacDermid, Incorporated, a Connecticut corporation.
|
|
MacDermid Acquisition
|
|
Platform’s acquisition on October 31, 2013 of substantially all of the equity of MacDermid Holdings, LLC, which, at the time, owned approximately 97% of MacDermid. As a result, Platform became a holding company for the MacDermid business. Platform acquired the remaining 3% of MacDermid on March 4, 2014, pursuant to the terms of the Exchange Agreement, dated October 25, 2013, between Platform and the fiduciaries of the MacDermid, Incorporated Profit Sharing and Employee Savings Plan.
|
|
MacDermid Printing
|
|
MacDermid Printing Solutions LLC, now known as MacDermid Graphics Solutions LLC.
|
|
NYSE
|
|
New York Stock Exchange.
|
|
PDH Common Stock
|
|
Shares of common stock of Platform Delaware Holdings, Inc., a subsidiary of Platform.
|
|
Proposed Separation
|
|
Platform's proposed separation of its Agricultural Solutions and Performance Solutions businesses, expected to be completed in 2018.
|
|
Quarterly Report
|
|
This quarterly report on Form 10-Q for the three months ended March 31, 2018.
|
|
Retaining Holder
|
|
Each Holder of an equity interest of MacDermid Holdings, LLC immediately prior to the closing of the MacDermid Acquisition, not owned by Platform, who executed a RHSA.
|
|
Revolving Credit Facility
|
|
Revolving credit facility (in U.S. Dollars or multicurrency) available under the Amended and Restated Credit Agreement.
|
|
RSUs
|
|
Restricted stock units issued by Platform from time to time under the 2013 Plan.
|
|
SEC
|
|
Securities and Exchange Commission.
|
|
Senior Notes
|
|
Platform's 5.875% USD Notes due 2025, 6.00% EUR Notes due 2023 and 6.50% USD Notes due 2022, collectively.
|
|
Series A Preferred Stock
|
|
2,000,000 shares of Platform’s Series A convertible preferred stock held by the Founder Entities and convertible into shares of Platform’s common stock, on a one-for-one basis, at any time at the option of the Founder Entities.
|
|
Terms
|
|
Definitions
|
|
Series B Convertible Preferred Stock
|
|
600,000 shares of Platform’s Series B convertible preferred stock issued to the Arysta Seller in connection with the Arysta Acquisition on February 13, 2015. At December 31, 2016, none of the Series B Convertible Preferred Stock remained outstanding.
|
|
TJCA
|
|
Tax Cuts and Jobs Act of 2017
|
|
2013 Plan
|
|
Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan adopted by the Board on October 31, 2013, as amended on December 16, 2013 and approved by Platform’s stockholders at the annual meeting held on June 12, 2014.
|
|
2017 Annual Report
|
|
Platform's annual report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on February 28, 2018.
|
|
5.875% USD Notes Indenture
|
|
The indenture, dated as of November 24, 2017, governing the 5.875% USD Notes due 2025.
|
|
5.875% USD Notes due 2025
|
|
Platform's 5.875% senior notes due 2023, denominated in U.S. dollars, issued in the 2017 Notes Offering.
|
|
6.00% EUR Senior Notes due 2023
|
|
Platform’s 6.00% senior notes due 2023 denominated in Euros issued in the February 2015 Notes Offering.
|
|
6.50% USD Senior Notes due 2022
|
|
Platform’s 6.50% senior notes due 2022 denominated in U.S. Dollars issued in the February 2015 Notes Offering.
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2018
|
|
2017
|
||||
|
Net sales
|
$
|
964.1
|
|
|
$
|
861.8
|
|
|
Cost of sales
|
559.4
|
|
|
483.4
|
|
||
|
Gross profit
|
404.7
|
|
|
378.4
|
|
||
|
Operating expenses:
|
|
|
|
|
|||
|
Selling, technical, general and administrative
|
277.0
|
|
|
257.4
|
|
||
|
Research and development
|
23.5
|
|
|
21.6
|
|
||
|
Total operating expenses
|
300.5
|
|
|
279.0
|
|
||
|
Operating profit
|
104.2
|
|
|
99.4
|
|
||
|
Other expense:
|
|
|
|
|
|
||
|
Interest expense, net
|
(78.2
|
)
|
|
(89.4
|
)
|
||
|
Foreign exchange gain (loss)
|
58.0
|
|
|
(12.6
|
)
|
||
|
Other income (expense), net
|
19.0
|
|
|
(2.3
|
)
|
||
|
Total other expense
|
(1.2
|
)
|
|
(104.3
|
)
|
||
|
Income (loss) before income taxes and non-controlling interests
|
103.0
|
|
|
(4.9
|
)
|
||
|
Income tax expense
|
(65.0
|
)
|
|
(18.7
|
)
|
||
|
Net income (loss)
|
38.0
|
|
|
(23.6
|
)
|
||
|
Net income attributable to the non-controlling interests
|
(0.7
|
)
|
|
(0.8
|
)
|
||
|
Net income (loss) attributable to common stockholders
|
$
|
37.3
|
|
|
$
|
(24.4
|
)
|
|
Earnings (loss) per share
|
|
|
|
|
|
||
|
Basic
|
$
|
0.13
|
|
|
$
|
(0.09
|
)
|
|
Diluted
|
$
|
0.13
|
|
|
$
|
(0.09
|
)
|
|
Weighted average common shares outstanding
|
|
|
|
|
|||
|
Basic
|
287.9
|
|
|
284.5
|
|
||
|
Diluted
|
293.8
|
|
|
284.5
|
|
||
|
|
Three Months Ended March 31,
|
||||||
|
|
2018
|
|
2017
|
||||
|
Net income (loss)
|
$
|
38.0
|
|
|
$
|
(23.6
|
)
|
|
|
|
|
|
|
|
||
|
Other comprehensive income (loss)
|
|
|
|
||||
|
Foreign currency translation adjustments
|
59.2
|
|
|
180.6
|
|
||
|
Pension and post-retirement plans:
|
|
|
|
||||
|
Other comprehensive loss net of tax benefit of $0.0 for the three months ended March 31, 2017
|
—
|
|
|
(0.3
|
)
|
||
|
Unrealized loss on available for sale securities:
|
|
|
|
||||
|
Other comprehensive loss net of tax of $0.0 for the three months ended March 31, 2017
|
|
|
(0.4
|
)
|
|||
|
Derivative financial instruments revaluation:
|
|
|
|
||||
|
Other comprehensive loss before reclassifications, net of tax expense of $2.2 and $0.0 for the three months ended March 31, 2018 and 2017, respectively
|
(2.7
|
)
|
|
(1.4
|
)
|
||
|
Reclassifications, net of tax expense of $0.0 for the three months ended March 31, 2018 and 2017
|
8.8
|
|
|
3.0
|
|
||
|
Total unrealized gain arising on qualified hedging derivatives
|
6.1
|
|
|
1.6
|
|
||
|
Other comprehensive income
|
65.3
|
|
|
181.5
|
|
||
|
|
|
|
|
||||
|
Comprehensive income
|
103.3
|
|
|
157.9
|
|
||
|
Comprehensive income attributable to the non-controlling interests
|
(2.2
|
)
|
|
(6.2
|
)
|
||
|
Comprehensive income attributable to common stockholders
|
$
|
101.1
|
|
|
$
|
151.7
|
|
|
|
March 31,
|
|
December 31,
|
||||
|
|
2018
|
|
2017
|
||||
|
Assets
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
412.6
|
|
|
$
|
477.8
|
|
|
Accounts receivable, net
|
1,289.4
|
|
|
1,156.0
|
|
||
|
Inventories
|
611.6
|
|
|
490.4
|
|
||
|
Prepaid expenses
|
48.4
|
|
|
42.8
|
|
||
|
Other current assets
|
190.1
|
|
|
173.6
|
|
||
|
Total current assets
|
2,552.1
|
|
|
2,340.6
|
|
||
|
Property, plant and equipment, net
|
451.0
|
|
|
452.3
|
|
||
|
Goodwill
|
4,276.4
|
|
|
4,201.2
|
|
||
|
Intangible assets, net
|
3,126.6
|
|
|
3,137.3
|
|
||
|
Other assets
|
141.1
|
|
|
121.0
|
|
||
|
Total assets
|
$
|
10,547.2
|
|
|
$
|
10,252.4
|
|
|
Liabilities and Stockholders' Equity
|
|
|
|
|
|
||
|
Accounts payable
|
$
|
498.1
|
|
|
$
|
461.8
|
|
|
Current installments of long-term debt and revolving credit facilities
|
116.3
|
|
|
38.9
|
|
||
|
Accrued expenses and other current liabilities
|
620.9
|
|
|
591.1
|
|
||
|
Total current liabilities
|
1,235.3
|
|
|
1,091.8
|
|
||
|
Debt and capital lease obligations
|
5,495.2
|
|
|
5,440.6
|
|
||
|
Pension and post-retirement benefits
|
70.1
|
|
|
69.0
|
|
||
|
Deferred income taxes
|
569.3
|
|
|
579.6
|
|
||
|
Contingent consideration
|
79.7
|
|
|
79.2
|
|
||
|
Other liabilities
|
130.6
|
|
|
132.2
|
|
||
|
Total liabilities
|
7,580.2
|
|
|
7,392.4
|
|
||
|
Commitments and contingencies (Note 13)
|
|
|
|
|
|
||
|
Stockholders' Equity
|
|
|
|
|
|
||
|
Preferred stock - Series A
|
—
|
|
|
—
|
|
||
|
Common stock: 400.0 shares authorized (2018: 288.1 shares issued; 2017: 287.4 shares issued)
|
2.9
|
|
|
2.9
|
|
||
|
Additional paid-in capital
|
4,043.6
|
|
|
4,032.0
|
|
||
|
Treasury stock (2018 and 2017: 0.0 shares)
|
(0.1
|
)
|
|
(0.1
|
)
|
||
|
Accumulated deficit
|
(833.7
|
)
|
|
(871.0
|
)
|
||
|
Accumulated other comprehensive loss
|
(356.9
|
)
|
|
(420.7
|
)
|
||
|
Total stockholders' equity
|
2,855.8
|
|
|
2,743.1
|
|
||
|
Non-controlling interests
|
111.2
|
|
|
116.9
|
|
||
|
Total equity
|
2,967.0
|
|
|
2,860.0
|
|
||
|
Total liabilities and stockholders' equity
|
$
|
10,547.2
|
|
|
$
|
10,252.4
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2018
|
|
2017
|
||||
|
Cash flows from operating activities:
|
|
|
|
||||
|
Net income (loss)
|
$
|
38.0
|
|
|
$
|
(23.6
|
)
|
|
Reconciliation of net income (loss) to net cash flows used in operating activities:
|
|
|
|
|
|
||
|
Depreciation and amortization
|
91.7
|
|
|
85.9
|
|
||
|
Deferred income taxes
|
(22.3
|
)
|
|
(14.2
|
)
|
||
|
Foreign exchange (gain) loss
|
(67.5
|
)
|
|
13.7
|
|
||
|
Other, net
|
(3.2
|
)
|
|
12.8
|
|
||
|
Changes in assets and liabilities, net of acquisitions:
|
|
|
|
||||
|
Accounts receivable
|
(133.9
|
)
|
|
(120.1
|
)
|
||
|
Inventories
|
(105.2
|
)
|
|
(83.9
|
)
|
||
|
Accounts payable
|
33.1
|
|
|
32.9
|
|
||
|
Accrued expenses
|
22.8
|
|
|
(15.9
|
)
|
||
|
Other assets and liabilities
|
(14.6
|
)
|
|
(7.0
|
)
|
||
|
Net cash flows used in operating activities
|
(161.1
|
)
|
|
(119.4
|
)
|
||
|
Cash flows from investing activities:
|
|
|
|
|
|
||
|
Capital expenditures
|
(10.0
|
)
|
|
(14.9
|
)
|
||
|
Investment in registrations of products
|
(13.2
|
)
|
|
(12.9
|
)
|
||
|
Proceeds from beneficial interests on sold accounts receivable
|
10.0
|
|
|
0.1
|
|
||
|
Proceeds from the sale of equity investment
|
25.0
|
|
|
—
|
|
||
|
Other, net
|
(5.0
|
)
|
|
2.4
|
|
||
|
Net cash flows provided by (used in) investing activities
|
6.8
|
|
|
(25.3
|
)
|
||
|
Cash flows from financing activities:
|
|
|
|
|
|
||
|
Change in lines of credit, net
|
74.5
|
|
|
89.0
|
|
||
|
Repayments of borrowings
|
(0.2
|
)
|
|
(9.0
|
)
|
||
|
Other, net
|
(0.1
|
)
|
|
(1.1
|
)
|
||
|
Net cash flows provided by financing activities
|
74.2
|
|
|
78.9
|
|
||
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
14.1
|
|
|
9.6
|
|
||
|
Net decrease in cash, cash equivalents and restricted cash
|
(66.0
|
)
|
|
(56.2
|
)
|
||
|
Cash, cash equivalents and restricted cash at beginning of period
|
483.9
|
|
|
423.5
|
|
||
|
Cash, cash equivalents and restricted cash at end of period
|
$
|
417.9
|
|
|
$
|
367.3
|
|
|
|
|
|
|
||||
|
Non-cash Investing Activities
|
|
|
|
|
|
||
|
Beneficial interests obtained in exchange for sold accounts receivable
|
$
|
14.4
|
|
|
$
|
0.6
|
|
|
|
Preferred Stock
|
|
Common Stock
|
|
Additional
Paid-in Capital |
|
Treasury Stock
|
|
Accumulated
Deficit |
|
Accumulated Other Comprehensive (Loss) Income
|
|
Total
Stockholders' Equity |
|
Non-
controlling Interests |
|
Total Equity
|
|||||||||||||||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
|
Shares
|
|
Amount
|
|
|
|
|
|
|||||||||||||||||||||||||||
|
Balance at December 31, 2017
|
2,000,000
|
|
|
$
|
—
|
|
|
287,405,939
|
|
|
$
|
2.9
|
|
|
$
|
4,032.0
|
|
|
6,618
|
|
|
$
|
(0.1
|
)
|
|
$
|
(869.7
|
)
|
|
$
|
(422.0
|
)
|
|
$
|
2,743.1
|
|
|
$
|
116.9
|
|
|
$
|
2,860.0
|
|
|
Impact of ASU 2016-01 adoption
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1.3
|
)
|
|
1.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||||
|
Adjusted balance at January 1, 2018
|
2,000,000
|
|
|
—
|
|
|
287,405,939
|
|
|
2.9
|
|
|
4,032.0
|
|
|
6,618
|
|
|
(0.1
|
)
|
|
(871.0
|
)
|
|
(420.7
|
)
|
|
2,743.1
|
|
|
116.9
|
|
|
2,860.0
|
|
|||||||||
|
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
37.3
|
|
|
—
|
|
|
37.3
|
|
|
0.7
|
|
|
38.0
|
|
|||||||||
|
Other comprehensive income, net of taxes
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
63.8
|
|
|
63.8
|
|
|
1.5
|
|
|
65.3
|
|
|||||||||
|
Exercise/ vesting of share based compensation
|
—
|
|
|
—
|
|
|
15,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||||
|
Conversion of PDH Common Stock into common stock
|
—
|
|
|
—
|
|
|
657,541
|
|
|
—
|
|
|
8.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
8.2
|
|
|
(8.2
|
)
|
|
—
|
|
|||||||||
|
Issuance of common stock under ESPP
|
—
|
|
|
—
|
|
|
37,364
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
|
0.3
|
|
|||||||||
|
Equity compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.1
|
|
|
—
|
|
|
3.1
|
|
|||||||||
|
Changes in non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.3
|
|
|
0.3
|
|
|||||||||
|
Balance at March 31, 2018
|
2,000,000
|
|
|
$
|
—
|
|
|
288,115,844
|
|
|
$
|
2.9
|
|
|
$
|
4,043.6
|
|
|
6,618
|
|
|
$
|
(0.1
|
)
|
|
$
|
(833.7
|
)
|
|
$
|
(356.9
|
)
|
|
$
|
2,855.8
|
|
|
$
|
111.2
|
|
|
$
|
2,967.0
|
|
|
|
Preferred Stock
|
|
Common Stock
|
|
Additional
Paid-in Capital |
|
Treasury Stock
|
|
Accumulated
Deficit |
|
Accumulated Other Comprehensive (Loss) Income
|
|
Total
Stockholders' Equity |
|
Non-
controlling Interests |
|
Total Equity
|
|||||||||||||||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
|
Shares
|
|
Amount
|
|
|
|
|
|
|||||||||||||||||||||||||||
|
Balance at December 31, 2016
|
2,000,000
|
|
|
$
|
—
|
|
|
284,221,168
|
|
|
$
|
2.8
|
|
|
$
|
3,981.3
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(573.5
|
)
|
|
$
|
(674.5
|
)
|
|
$
|
2,736.1
|
|
|
$
|
153.7
|
|
|
$
|
2,889.8
|
|
|
Net (loss) income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(24.4
|
)
|
|
—
|
|
|
(24.4
|
)
|
|
0.8
|
|
|
(23.6
|
)
|
|||||||||
|
Other comprehensive income, net of taxes
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
176.1
|
|
|
176.1
|
|
|
5.4
|
|
|
181.5
|
|
|||||||||
|
Exercise/ vesting of share based compensation
|
—
|
|
|
—
|
|
|
48,721
|
|
|
—
|
|
|
—
|
|
|
6,618
|
|
|
(0.1
|
)
|
|
—
|
|
|
—
|
|
|
(0.1
|
)
|
|
—
|
|
|
(0.1
|
)
|
|||||||||
|
Conversion of PDH Common Stock into common stock
|
—
|
|
|
—
|
|
|
1,356,483
|
|
|
—
|
|
|
16.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
16.5
|
|
|
(16.5
|
)
|
|
—
|
|
|||||||||
|
Issuance of common stock under ESPP
|
—
|
|
|
—
|
|
|
37,980
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
|
0.3
|
|
|||||||||
|
Equity compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.5
|
|
|
—
|
|
|
2.5
|
|
|||||||||
|
Changes in non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.5
|
)
|
|
(0.5
|
)
|
|||||||||
|
Balance at March 31, 2017
|
2,000,000
|
|
|
$
|
—
|
|
|
285,664,352
|
|
|
$
|
2.8
|
|
|
$
|
4,000.6
|
|
|
6,618
|
|
|
$
|
(0.1
|
)
|
|
$
|
(597.9
|
)
|
|
$
|
(498.4
|
)
|
|
$
|
2,907.0
|
|
|
$
|
142.9
|
|
|
$
|
3,049.9
|
|
|
•
|
Off-balance sheet arrangements, whereby the Company sells trade receivables to third parties without recourse and receives beneficial interests for a portion of these receivables, the proceeds of which were previously reported as “Operating Activities” in the Condensed Consolidated Statements of Cash Flows. For the three months ended March 31, 2017,
$0.6 million
of beneficial interests from the sale of trade receivables were reclassified as non-cash activity, with cash receipts of approximately
$0.1 million
reclassified as cash inflows from "Investing Activities" in the applicable Condensed Consolidated Statements of Cash Flows.
|
|
•
|
For the three months ended March 31, 2017, cash payments for debt prepayments and debt extinguishment costs of
$1.1 million
were reclassified from "Operating Activities" to "Financing Activities" in the applicable Consolidated Statements of Cash Flows.
|
|
(amounts in millions)
|
March 31,
2018 |
|
December 31,
2017 |
||||
|
Cash and cash equivalents
|
$
|
412.6
|
|
|
$
|
477.8
|
|
|
Restricted cash included in "Other current assets"
|
5.3
|
|
|
6.1
|
|
||
|
Cash, cash equivalents and restricted cash
|
$
|
417.9
|
|
|
$
|
483.9
|
|
|
(amounts in millions)
|
March 31,
2018 |
|
December 31,
2017 |
||||
|
Total accounts receivable, net
|
$
|
1,315.8
|
|
|
$
|
1,157.7
|
|
|
Non-current accounts receivable, net
|
(26.4
|
)
|
|
(1.7
|
)
|
||
|
Current accounts receivable, net
|
$
|
1,289.4
|
|
|
$
|
1,156.0
|
|
|
(amounts in millions)
|
March 31,
2018 |
|
December 31,
2017 |
||||
|
Finished goods
|
$
|
401.4
|
|
|
$
|
328.9
|
|
|
Work in process
|
28.1
|
|
|
28.8
|
|
||
|
Raw materials and supplies
|
197.9
|
|
|
149.8
|
|
||
|
Total inventory, net
|
627.4
|
|
|
507.5
|
|
||
|
Non-current inventory, net
|
(15.8
|
)
|
|
(17.1
|
)
|
||
|
Current inventory, net
|
$
|
611.6
|
|
|
$
|
490.4
|
|
|
(amounts in millions)
|
March 31,
2018 |
|
December 31,
2017 |
||||
|
Land and leasehold improvements
|
$
|
109.9
|
|
|
$
|
108.8
|
|
|
Buildings and improvements
|
159.4
|
|
|
149.8
|
|
||
|
Machinery, equipment, fixtures and software
|
362.1
|
|
|
344.6
|
|
||
|
Construction in process
|
31.7
|
|
|
34.3
|
|
||
|
Total property, plant and equipment
|
663.1
|
|
|
637.5
|
|
||
|
Accumulated depreciation
|
(212.1
|
)
|
|
(185.2
|
)
|
||
|
Property, plant and equipment, net
|
$
|
451.0
|
|
|
$
|
452.3
|
|
|
(amounts in millions)
|
Performance
Solutions
|
|
Agricultural Solutions
|
|
Total
|
||||||
|
Balance at December 31, 2017
|
|
|
|
|
|
||||||
|
Goodwill
|
$
|
2,299.2
|
|
|
$
|
2,108.6
|
|
|
$
|
4,407.8
|
|
|
Accumulated impairment losses
|
(46.6
|
)
|
|
(160.0
|
)
|
|
(206.6
|
)
|
|||
|
|
2,252.6
|
|
|
1,948.6
|
|
|
4,201.2
|
|
|||
|
Foreign currency translation and other
|
45.5
|
|
|
29.7
|
|
|
75.2
|
|
|||
|
Balance at March 31, 2018
|
|
|
|
|
|
||||||
|
Goodwill
|
2,344.7
|
|
|
2,138.3
|
|
|
4,483.0
|
|
|||
|
Accumulated impairment losses
|
(46.6
|
)
|
|
(160.0
|
)
|
|
(206.6
|
)
|
|||
|
|
$
|
2,298.1
|
|
|
$
|
1,978.3
|
|
|
$
|
4,276.4
|
|
|
|
March 31, 2018
|
|
December 31, 2017
|
||||||||||||||||||||
|
(amounts in millions)
|
Gross Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net Book
Value
|
|
Gross Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net Book
Value
|
||||||||||||
|
Customer lists
|
$
|
1,327.5
|
|
|
$
|
(289.9
|
)
|
|
$
|
1,037.6
|
|
|
$
|
1,303.3
|
|
|
$
|
(263.5
|
)
|
|
$
|
1,039.8
|
|
|
Developed technology
(1)
|
2,295.0
|
|
|
(614.4
|
)
|
|
1,680.6
|
|
|
2,250.7
|
|
|
(557.0
|
)
|
|
1,693.7
|
|
||||||
|
Tradenames
|
31.0
|
|
|
(15.3
|
)
|
|
15.7
|
|
|
30.3
|
|
|
(13.8
|
)
|
|
16.5
|
|
||||||
|
Non-compete agreements
|
2.8
|
|
|
(1.4
|
)
|
|
1.4
|
|
|
2.8
|
|
|
(1.3
|
)
|
|
1.5
|
|
||||||
|
Total
|
$
|
3,656.3
|
|
|
$
|
(921.0
|
)
|
|
$
|
2,735.3
|
|
|
$
|
3,587.1
|
|
|
$
|
(835.6
|
)
|
|
$
|
2,751.5
|
|
|
(amounts in millions)
|
Maturity Date
|
|
Interest Rate
|
|
March 31,
2018 |
|
December 31,
2017 |
||||
|
USD Senior Notes
(1)
|
2022
|
|
6.50%
|
|
$
|
1,086.8
|
|
|
$
|
1,086.1
|
|
|
EUR Senior Notes
(1)
|
2023
|
|
6.00%
|
|
426.7
|
|
|
415.1
|
|
||
|
USD Senior Notes
(1)
|
2025
|
|
5.875%
|
|
783.6
|
|
|
783.2
|
|
||
|
First Lien Credit Facility - USD Term Loans
(2)
|
2020
|
|
> of 3.50% or
LIBOR plus 2.50% |
|
621.3
|
|
|
620.4
|
|
||
|
First Lien Credit Facility - USD Term Loans
(2) (3)
|
2021
|
|
> of 4.00% or
LIBOR plus 3.00% |
|
1,122.1
|
|
|
1,121.2
|
|
||
|
First Lien Credit Facility - Euro Term Loans
(2)
|
2020
|
|
> of 3.25% or EURIBOR plus 2.5%
|
|
713.7
|
|
|
694.3
|
|
||
|
First Lien Credit Facility - Euro Term Loans
(2) (3)
|
2021
|
|
> of 3.50% or EURIBOR plus 2.75%
|
|
735.6
|
|
|
716.0
|
|
||
|
Borrowings under the Revolving Credit Facility
|
|
|
LIBOR plus 3.00%
|
|
52.0
|
|
|
—
|
|
||
|
Borrowings under lines of credit
(4)
|
|
|
|
|
50.6
|
|
|
28.5
|
|
||
|
Other
|
|
|
|
|
19.1
|
|
|
14.7
|
|
||
|
Total debt and capital lease obligations
|
|
|
|
|
5,611.5
|
|
|
5,479.5
|
|
||
|
Less: current installments of long-term debt and revolving credit facilities
|
|
|
|
|
116.3
|
|
|
38.9
|
|
||
|
Total long-term debt and capital lease obligations
|
|
|
|
|
$
|
5,495.2
|
|
|
$
|
5,440.6
|
|
|
(1)
|
Net of unamortized premium, discounts, and debt issuance costs of
$34.2 million
and
$35.5 million
at
March 31, 2018
and
December 31, 2017
, respectively. Weighted average effective interest rate of
6.53%
at
March 31, 2018
and
December 31, 2017
.
|
|
(2)
|
First Lien Credit Facility term loans net of unamortized discounts and debt issuance costs of
$30.9 million
and
$33.3 million
at
March 31, 2018
and
December 31, 2017
, respectively. Weighted average effective interest rate of
4.58%
and
4.53%
at
March 31, 2018
and
December 31, 2017
, respectively, including the effects of interest rate swaps. See Note 10, Financial Instruments, to the Company's unaudited interim Condensed Consolidated Financial Statements for further information regarding the Company's interest rate swaps.
|
|
(3)
|
The maturity date will extend to June 7, 2023, provided that the Company is able to prepay, redeem or otherwise retire and/or refinance in full its
$1.10 billion
6.50%
USD Senior Notes due 2022, as permitted under the Amended and Restated Credit Agreement, on or prior to November 2, 2021.
|
|
(4)
|
Weighted average interest rate of
3.91%
and
3.51%
at
March 31, 2018
and
December 31, 2017
, respectively.
|
|
|
|
|
Three Months Ended
March 31, |
||||||
|
(amounts in millions)
|
|
|
2018
|
|
2017
|
||||
|
Derivatives not designated as hedging instruments:
|
Location on Condensed Consolidated Statement of Operations:
|
|
|
|
|
||||
|
Foreign exchange and metals contracts
|
Other income (expense), net
|
|
$
|
(2.0
|
)
|
|
$
|
(1.4
|
)
|
|
|
March 31, 2018
|
|
December 31, 2017
|
||||||||||||
|
(amounts in millions)
|
Asset
|
|
Liability
|
|
Asset
|
|
Liability
|
||||||||
|
Gross amounts
|
$
|
5.0
|
|
|
$
|
6.8
|
|
|
$
|
5.5
|
|
|
$
|
6.2
|
|
|
Gross amount subject to offset in master netting arrangements that are not offset
|
(1.6
|
)
|
|
(1.8
|
)
|
|
(1.0
|
)
|
|
(2.0
|
)
|
||||
|
Cash collateral paid
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.4
|
)
|
||||
|
Net
|
$
|
3.4
|
|
|
$
|
5.0
|
|
|
$
|
4.5
|
|
|
$
|
3.8
|
|
|
(amounts in millions)
|
Balance sheet location
|
|
Classification
|
|
March 31,
2018
|
|
December 31, 2017
|
||||
|
Asset Category
|
|
|
|
|
|
|
|
||||
|
Foreign exchange and metals contracts not designated as hedging instruments
|
Other current assets
|
|
Level 2
|
|
$
|
6.4
|
|
|
$
|
5.5
|
|
|
Available for sale equity securities
|
Other assets
|
|
Level 1
|
|
3.3
|
|
|
3.7
|
|
||
|
Interest rate swaps designated as cash flow hedging instruments
|
Other current assets
|
|
Level 2
|
|
2.0
|
|
|
—
|
|
||
|
Interest rate swaps designated as cash flow hedging instruments
|
Other assets
|
|
Level 2
|
|
8.4
|
|
|
3.4
|
|
||
|
Available for sale equity securities
|
Other assets
|
|
Level 2
|
|
0.1
|
|
|
0.6
|
|
||
|
Total
|
|
|
|
|
$
|
20.2
|
|
|
$
|
13.2
|
|
|
|
|
|
|
|
|
|
|
||||
|
Liability Category
|
|
|
|
|
|
|
|
||||
|
Interest rate swaps designated as cash flow hedging instruments
|
Accrued expenses and other liabilities
|
|
Level 2
|
|
$
|
0.7
|
|
|
$
|
2.8
|
|
|
Foreign exchange and metals contracts not designated as hedging instruments
|
Accrued expenses and other liabilities
|
|
Level 2
|
|
7.1
|
|
|
7.3
|
|
||
|
Interest rate swaps designated as cash flow hedging instruments
|
Other liabilities
|
|
Level 2
|
|
0.7
|
|
|
0.8
|
|
||
|
Long-term contingent consideration
|
Contingent consideration
|
|
Level 3
|
|
79.7
|
|
|
79.2
|
|
||
|
Total
|
|
|
|
|
$
|
88.2
|
|
|
$
|
90.1
|
|
|
•
|
Common Stock - The common stock performance target, which represents an expected future payment value of
$40.0 million
, has been satisfied and is recorded at its present value utilizing a discount rate of approximately
2.38%
. An increase or decrease in the discount rate of
1%
changes the fair value measure of the metric by approximately
$1.1 million
.
|
|
•
|
Adjusted EBITDA - The estimated fair value of the Adjusted EBITDA performance metric is derived using the income approach with unobservable inputs, based on future forecasts and present value assumptions which include a discount rate of approximately
10.00%
and expected future payment value of
$60.0 million
calculated using a probability weighted Adjusted EBITDA assessment with higher probability associated with the Company achieving the maximum Adjusted EBITDA targets. An increase or a decrease in the discount rate of
1%
, within a range of probability between
80%
and
100%
, changes the estimated fair value measure of the metric by approximately
$1.5 million
.
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions, except per share amounts)
|
2018
|
|
2017
|
||||
|
Net income (loss) attributable to common stockholders
|
$
|
37.3
|
|
|
$
|
(24.4
|
)
|
|
Numerator adjustments for diluted EPS:
|
|
|
|
||||
|
Remeasurement of contingent consideration
|
0.2
|
|
|
—
|
|
||
|
Numerator adjustments for diluted EPS:
|
0.2
|
|
|
—
|
|
||
|
Net income (loss) attributable to common stockholders for diluted EPS
|
$
|
37.5
|
|
|
$
|
(24.4
|
)
|
|
|
|
|
|
||||
|
Basic weighted average common shares outstanding
|
287.9
|
|
|
284.5
|
|
||
|
Denominator adjustments for diluted EPS:
|
|
|
|
||||
|
Number of shares issuable upon conversion of founder preferred stock
|
2.0
|
|
|
—
|
|
||
|
Number of shares contingently issuable for the contingent consideration
|
3.3
|
|
|
—
|
|
||
|
Number of stock options, RSUs and shares issued through employee stock purchase plan
|
0.6
|
|
|
—
|
|
||
|
Denominator adjustments for diluted EPS:
|
5.9
|
|
|
—
|
|
||
|
Dilutive weighted average common shares outstanding
|
293.8
|
|
|
284.5
|
|
||
|
Earnings (loss) per share attributable to common stockholders:
|
|
|
|
|
|
||
|
Basic
|
$
|
0.13
|
|
|
$
|
(0.09
|
)
|
|
Diluted
|
$
|
0.13
|
|
|
$
|
(0.09
|
)
|
|
|
|
|
|
||||
|
Dividends per share paid to common stockholders
|
$
|
—
|
|
|
$
|
—
|
|
|
|
Three Months Ended March 31,
|
||||
|
(amounts in thousands)
|
2018
|
|
2017
|
||
|
Shares issuable upon conversion of PDH Common Stock
|
4,317
|
|
|
7,504
|
|
|
Shares issuable upon conversion of Series A Preferred Stock
|
—
|
|
|
2,000
|
|
|
Shares issuable for the contingent consideration
|
5,427
|
|
|
6,141
|
|
|
Shares issuable upon vesting and exercise of stock options
|
—
|
|
|
49
|
|
|
Shares issuable upon vesting of RSUs
|
517
|
|
|
711
|
|
|
Shares issuable under the ESPP
|
—
|
|
|
6
|
|
|
Total
|
10,261
|
|
|
16,411
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2018
|
|
2017
|
||||
|
Net Sales:
|
|
|
|
||||
|
Performance Solutions
|
|
|
|
||||
|
Assembly Solutions
|
$
|
145.9
|
|
|
$
|
133.4
|
|
|
Industrial Solutions
|
145.5
|
|
|
128.0
|
|
||
|
Electronics Solutions
|
142.1
|
|
|
129.2
|
|
||
|
Graphics Solutions
|
38.7
|
|
|
37.4
|
|
||
|
Offshore Solutions
|
20.2
|
|
|
19.1
|
|
||
|
Performance Solutions net sales
|
492.4
|
|
|
447.1
|
|
||
|
Agricultural Solutions
|
|
|
|
||||
|
EMEA (Europe, Middle East and Africa)
|
253.5
|
|
|
215.1
|
|
||
|
LATAM (Latin America)
|
108.8
|
|
|
98.7
|
|
||
|
NAANZ (North America, Australia and New Zealand)
|
61.7
|
|
|
55.6
|
|
||
|
ASIA
|
42.9
|
|
|
42.1
|
|
||
|
AAH (Animal Health)
|
4.8
|
|
|
3.2
|
|
||
|
Agricultural Solutions net sales
|
471.7
|
|
|
414.7
|
|
||
|
Total net sales
|
$
|
964.1
|
|
|
$
|
861.8
|
|
|
|
|
|
|
||||
|
Adjusted EBITDA:
|
|
|
|
|
|
||
|
Performance Solutions
|
$
|
111.8
|
|
|
$
|
102.3
|
|
|
Agricultural Solutions
|
95.4
|
|
|
90.8
|
|
||
|
Total Adjusted EBITDA
|
$
|
207.2
|
|
|
$
|
193.1
|
|
|
|
Three months ended March 31,
|
||||||
|
(amounts in millions)
|
2018
|
|
2017
|
||||
|
Net income (loss) attributable to common stockholders
|
$
|
37.3
|
|
|
$
|
(24.4
|
)
|
|
Add (subtract):
|
|
|
|
||||
|
Net income attributable to the non-controlling interests
|
0.7
|
|
|
0.8
|
|
||
|
Income tax expense
|
65.0
|
|
|
18.7
|
|
||
|
Interest expense, net
|
78.2
|
|
|
89.4
|
|
||
|
Depreciation expense
|
19.8
|
|
|
17.3
|
|
||
|
Amortization expense
|
71.9
|
|
|
68.6
|
|
||
|
EBITDA
|
272.9
|
|
|
170.4
|
|
||
|
Adjustments to reconcile to Adjusted EBITDA:
|
|
|
|
||||
|
Restructuring expense
|
3.0
|
|
|
2.3
|
|
||
|
Acquisition and integration costs
|
1.0
|
|
|
3.6
|
|
||
|
Non-cash change in fair value of contingent consideration
|
0.5
|
|
|
1.1
|
|
||
|
Foreign exchange (gain) loss on foreign denominated external and internal long-term debt
|
(55.8
|
)
|
|
11.8
|
|
||
|
Nonrecourse factoring costs
|
1.1
|
|
|
0.7
|
|
||
|
Debt refinancing costs
|
—
|
|
|
1.1
|
|
||
|
Costs related to Proposed Separation
|
3.1
|
|
|
0.2
|
|
||
|
Gain on sale of equity investment
|
(11.3
|
)
|
|
—
|
|
||
|
Other, net
|
(7.3
|
)
|
|
1.9
|
|
||
|
Adjusted EBITDA
|
$
|
207.2
|
|
|
$
|
193.1
|
|
|
Assembly Solutions:
|
|
The business develops, manufactures and sells innovative interconnected materials, primarily in the electronics market, used to assemble printed circuit boards and advanced semiconductor packaging.
|
|
Electronics Solutions:
|
|
The business designs and formulates a complete line of proprietary “wet” dynamic chemistries used by customers to process the surface of printed circuit boards and other electronic components they manufacture.
|
|
Industrial Solutions
|
|
The business' dynamic chemistries are used for finishing, cleaning and providing surface coatings for a broad range of metal and non-metal surfaces which improve the performance or look of a component of an industrial part or process.
|
|
Graphics Solutions:
|
|
The business produces photopolymers, through an extensive line of flexographic plates, which are used to produce printing plates for transferring images onto commercial packaging, including packaging for consumer food products, pet food bags, corrugated boxes, labels and beverage containers. In addition, the segment produces photopolymer printing plates for the flexographic and letterpress newspaper and publications markets.
|
|
Offshore Solutions:
|
|
The business produces water-based hydraulic control fluids for major oil and gas companies and drilling contractors for offshore deep water production and drilling applications.
|
|
Crop Protection:
|
|
The Crop Protection business is one of the largest Crop Protection chemical companies by revenue. Its diverse Crop Protection chemicals control biotic stresses, such as diseases (fungicides), weeds (herbicides) and insects (insecticides).
|
|
BioSolutions:
|
|
The segment believes its BioSolutions business has a strong position as innovator in BioSolutions and BioStimulants. These products are derived from natural sources that fall into several categories: biological stimulants (BioStimulants), Innovative Nutrition and biological control (BioControl). This portfolio is highly differentiated through innovative technologies and mixtures and primarily protected by trade secrets.
|
|
Seed Treatment:
|
|
The segment's diverse Seed Treatments are applied before planting by coating the seed in order to protect it during germination and protect the plant during its initial growth phases. The segment anticipates growth in Seed Treatments as a result of the increasing value of seeds and the use of higher-value genetically-modified seeds.
|
|
|
Three Months Ended March 31,
|
|
% Change
|
||||||||||
|
($ amounts in millions)
|
2018
|
|
2017
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
|
Net sales
|
$
|
964.1
|
|
|
$
|
861.8
|
|
|
12%
|
|
5%
|
|
5%
|
|
Cost of sales
|
559.4
|
|
|
483.4
|
|
|
16%
|
|
9%
|
|
|
||
|
Gross profit
|
404.7
|
|
|
378.4
|
|
|
7%
|
|
—%
|
|
|
||
|
Selling, technical, general and administrative
|
277.0
|
|
|
257.4
|
|
|
8%
|
|
3%
|
|
|
||
|
Research and development
|
23.5
|
|
|
21.6
|
|
|
9%
|
|
6%
|
|
|
||
|
Operating profit
|
104.2
|
|
|
99.4
|
|
|
5%
|
|
(9)%
|
|
|
||
|
Interest expense, net
|
(78.2
|
)
|
|
(89.4
|
)
|
|
(13)%
|
|
|
|
|
||
|
Foreign exchange gain (loss)
|
58.0
|
|
|
(12.6
|
)
|
|
nm
|
|
|
|
|
||
|
Other income (expense), net
|
19.0
|
|
|
(2.3
|
)
|
|
nm
|
|
|
|
|
||
|
Income tax expense
|
(65.0
|
)
|
|
(18.7
|
)
|
|
nm
|
|
|
|
|
||
|
Net income (loss)
|
$
|
38.0
|
|
|
$
|
(23.6
|
)
|
|
nm
|
|
|
|
|
|
(nm)
|
Calculation not meaningful.
|
|
|
Three Months Ended March 31, 2018
|
||||||||
|
|
Reported Net Sales Growth
|
|
Impact of Currency
|
|
Metals
|
|
Acquisitions
|
|
Organic Sales Growth
|
|
Performance Solutions
|
10%
|
|
(7)%
|
|
1%
|
|
—%
|
|
4%
|
|
Agricultural Solutions
|
14%
|
|
(7)%
|
|
—%
|
|
—%
|
|
6%
|
|
Total
|
12%
|
|
(7)%
|
|
—%
|
|
—%
|
|
5%
|
|
|
Three Months Ended March 31,
|
|
% Change
|
||||||||||
|
($ amounts in millions)
|
2018
|
|
2017
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
|
Performance Solutions
|
$
|
492.4
|
|
|
$
|
447.1
|
|
|
10%
|
|
3%
|
|
4%
|
|
Agricultural Solutions
|
471.7
|
|
|
414.7
|
|
|
14%
|
|
6%
|
|
6%
|
||
|
Total
|
$
|
964.1
|
|
|
$
|
861.8
|
|
|
12%
|
|
5%
|
|
5%
|
|
|
Three Months Ended March 31,
|
|
% Change
|
||||||||
|
($ amounts in millions)
|
2018
|
|
2017
|
|
Reported
|
|
Constant Currency
|
||||
|
Gross profit
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
211.2
|
|
|
$
|
196.8
|
|
|
7%
|
|
1%
|
|
Agricultural Solutions
|
193.5
|
|
|
181.6
|
|
|
7%
|
|
(2)%
|
||
|
Total
|
$
|
404.7
|
|
|
$
|
378.4
|
|
|
7%
|
|
—%
|
|
|
|
|
|
|
|
|
|
||||
|
Gross margin
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
42.9%
|
|
44.0%
|
|
(110) bps
|
|
(90) bps
|
||||
|
Agricultural Solutions
|
41.0%
|
|
43.8%
|
|
(280) bps
|
|
(340) bps
|
||||
|
Total
|
42.0%
|
|
43.9%
|
|
(190) bps
|
|
(210) bps
|
||||
|
|
Three Months Ended March 31,
|
|
% Change
|
||||||||
|
($ amounts in millions)
|
2018
|
|
2017
|
|
Reported
|
|
Constant Currency
|
||||
|
STG&A
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
122.8
|
|
|
$
|
118.7
|
|
|
3%
|
|
(2)%
|
|
Agricultural Solutions
|
133.3
|
|
|
119.0
|
|
|
12%
|
|
7%
|
||
|
Corporate
|
20.9
|
|
|
19.7
|
|
|
6%
|
|
6%
|
||
|
Total
|
$
|
277.0
|
|
|
$
|
257.4
|
|
|
8%
|
|
3%
|
|
|
|
|
|
|
|
|
|
||||
|
STG&A as a % of net sales
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
24.9%
|
|
26.5%
|
|
(160) bps
|
|
(140) bps
|
||||
|
Agricultural Solutions
|
28.3%
|
|
28.7%
|
|
(40) bps
|
|
20 bps
|
||||
|
Total
|
28.7%
|
|
29.9%
|
|
(120) bps
|
|
(60) bps
|
||||
|
|
Three Months Ended March 31,
|
|
% Change
|
||||||||
|
($ amounts in millions)
|
2018
|
|
2017
|
|
Reported
|
|
Constant Currency
|
||||
|
R&D
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
11.4
|
|
|
$
|
11.0
|
|
|
4%
|
|
3%
|
|
Agricultural Solutions
|
12.1
|
|
|
10.6
|
|
|
14%
|
|
10%
|
||
|
Total
|
$
|
23.5
|
|
|
$
|
21.6
|
|
|
9%
|
|
6%
|
|
|
|
|
|
|
|
|
|
||||
|
R&D as a % of net sales
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
2.3%
|
|
2.4%
|
|
(10) bps
|
|
0 bps
|
||||
|
Agricultural Solutions
|
2.6%
|
|
2.6%
|
|
0 bps
|
|
10 bps
|
||||
|
Total
|
2.4%
|
|
2.5%
|
|
(10) bps
|
|
0 bps
|
||||
|
|
Three Months Ended March 31,
|
|
% Change
|
||||||||
|
($ amounts in millions)
|
2018
|
|
2017
|
|
Reported
|
|
Constant Currency
|
||||
|
Operating profit
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
77.0
|
|
|
$
|
67.2
|
|
|
15%
|
|
7%
|
|
Agricultural Solutions
|
48.1
|
|
|
51.9
|
|
|
(7)%
|
|
(25)%
|
||
|
Corporate
|
(20.9
|
)
|
|
(19.7
|
)
|
|
6%
|
|
6%
|
||
|
Total
|
$
|
104.2
|
|
|
$
|
99.4
|
|
|
5%
|
|
(9)%
|
|
|
|
|
|
|
|
|
|
||||
|
Operating margin
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
15.6%
|
|
15.0%
|
|
60 bps
|
|
50 bps
|
||||
|
Agricultural Solutions
|
10.2%
|
|
12.5%
|
|
(230) bps
|
|
(370) bps
|
||||
|
Total
|
10.8%
|
|
11.5%
|
|
(70) bps
|
|
(160) bps
|
||||
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2018
|
|
2017
|
||||
|
Interest expense, net
|
$
|
(78.2
|
)
|
|
$
|
(89.4
|
)
|
|
Foreign exchange gain (loss)
|
58.0
|
|
|
(12.6
|
)
|
||
|
Other income (expense), net
|
19.0
|
|
|
(2.3
|
)
|
||
|
Total
|
$
|
(1.2
|
)
|
|
$
|
(104.3
|
)
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2018
|
|
2017
|
||||
|
Income tax expense
|
$
|
(65.0
|
)
|
|
$
|
(18.7
|
)
|
|
Effective tax rate
|
63.1
|
%
|
|
(381.6
|
)%
|
||
|
|
Three Months Ended March 31,
|
|
% Change
|
||||||||
|
($ amounts in millions)
|
2018
|
|
2017
|
|
Reported
|
|
Constant Currency
|
||||
|
Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
||
|
Performance Solutions
|
$
|
111.8
|
|
|
$
|
102.3
|
|
|
9%
|
|
2%
|
|
Agricultural Solutions
|
95.4
|
|
|
90.8
|
|
|
5%
|
|
(8)%
|
||
|
Total
|
$
|
207.2
|
|
|
$
|
193.1
|
|
|
7%
|
|
(3)%
|
|
|
|
|
|
|
|
|
|
||||
|
Adjusted EBITDA as a % of net sales
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
22.7%
|
|
22.9%
|
|
(20) bps
|
|
(30) bps
|
||||
|
Agricultural Solutions
|
20.2%
|
|
21.9%
|
|
(170) bps
|
|
(290) bps
|
||||
|
Total
|
21.5%
|
|
22.4%
|
|
(90) bps
|
|
(160) bps
|
||||
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2018
|
|
2017
|
||||
|
Cash, cash equivalents and restricted cash, beginning of the period
|
$
|
483.9
|
|
|
$
|
423.5
|
|
|
Cash used in operating activities
|
(161.1
|
)
|
|
(119.4
|
)
|
||
|
Cash provided by (used in) investing activities
|
6.8
|
|
|
(25.3
|
)
|
||
|
Cash provided by financing activities
|
74.2
|
|
|
78.9
|
|
||
|
Exchange rate impact on cash, cash equivalents and restricted cash
|
14.1
|
|
|
9.6
|
|
||
|
Cash, cash equivalents and restricted cash, end of the period
|
$
|
417.9
|
|
|
$
|
367.3
|
|
|
•
|
$2.30 billion
of Senior Notes;
|
|
•
|
$3.19 billion
of term debt arrangements outstanding under our First Lien Credit Facility; and
|
|
•
|
$103 million
of borrowings under local and revolving lines of credit.
|
|
•
|
improving the overall tax provision process; and
|
|
•
|
enhancing our income tax controls to include specific activities to assess the accounting for significant complex transactions and other tax related judgments.
|
|
Exhibit
Number
|
Description
|
|
3.1(a)
|
Certificate of Incorporation
(filed as Exhibit 3.1 of Post-Effective Amendment No. 1 to the Registration Statement on Form S-4 (File No. 333-192778) filed on January 24, 2014, and incorporated herein by reference)
|
|
3.1(b)
|
Certificate of Amendment of Certificate of Incorporation
(filed as Exhibit 3.1 of the Current Report on Form 8-K filed on June 13, 2014, and incorporated herein by reference)
|
|
3.2
|
Amended and Restated By-laws
(filed as Exhibit 3.2 of the Annual Report on Form 10-K filed on March 31, 2014, and incorporated herein by reference)
|
|
10.1
|
Second Amended and Restated Credit Agreement, dated as of August 6, 2014
, among, inter alia, the Company, MacDermid Holdings, LLC, MacDermid, Incorporated, the subsidiaries of the borrower from time to time parties thereto, the lenders from time to time parties thereto and Barclays Bank PLC, as administrative agent and collateral agent (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 8, 2014, and incorporated herein by reference)
|
|
10.2
|
Amendment No. 9, dated March 21, 2018
, among, inter alios, the Company, MacDermid, Incorporated, certain subsidiaries of the Company parties thereto, the lenders parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent (filed as Exhibit 10.1 of the Current Report on Form 8-K filed on March 23, 2018, and incorporated herein by reference)
|
|
10.3
|
Amended and Restated Pledge and Security Agreement, dated as of October 31, 2013
, among the Company, MacDermid Holdings, LLC, MacDermid, Incorporated and the subsidiaries of the borrowers from time to time parties thereto in favor of Barclays Bank PLC, as collateral agent (filed as Exhibit 10.25 to the Company’s Annual Report on Form 10-K filed on March 31, 2014, and incorporated herein by reference)
|
|
10.4†
|
Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
(filed as Appendix A to Platform’s Definitive Proxy Statement, as filed on April 25, 2014, and incorporated herein by reference)
|
|
31.1*
|
|
|
31.2*
|
|
|
32.1**
|
|
|
101. INS*
|
XBRL Instance Document
|
|
101.SCH*
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL*
|
XBRL Extension Calculation Linkbase Document
|
|
101.DEF*
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB*
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE*
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
PLATFORM SPECIALTY PRODUCTS CORPORATION
|
|
|
|
|
|
|
|
By:
|
/s/ John P. Connolly
|
|
|
|
John P. Connolly
|
|
|
|
Chief Financial Officer
|
|
|
|
(Principal Financial Officer)
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|